Skip to content

Study · Systematic review · n = 5,032 · 2017

5 results

Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.

Ayers D, Kanters S, Goldgrub R, Hughes M, Kato R, Kragh N

Current medical research and opinion19 Jul 2017Cited by 6 (Europe PMC)

PMID28635331 (opens in a new tab)DOI10.1080/03007995.2017.1345730 (opens in a new tab)PepBankPUB-28635331
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In Japanese adults with uncontrolled type 2 diabetes, liraglutide 0.9 mg lowered HbA1c significantly more than each DPP-4 inhibitor at 12 weeks.

    In plain wordsIn Japanese adults with type 2 diabetes, liraglutide 0.9 mg lowered HbA1c more than each DPP-4 inhibitor at 12 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at 12 weeks, liraglutide 0.9 mg vs DPP-4 inhibitors
    Study

    n = 5,032

    Comparator
    DPP-4 inhibitors
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide 0.9 mg was statistically superior to all DPP-4 interventions (vildagliptin, sitagliptin, linagliptin, alogliptin, teneligliptin, trelagliptin and omarigliptin) at 12 weeks and 24 weeks among those reporting.
    2 context sentences
    Summary · context
    A total of 27 trials (5032 patients) reported change in HbA1c at 12 weeks and at 24 weeks 9 trials (2091 patients).
    Summary · context
    We searched for randomized controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016.
  2. 02HumanSystematic reviewEfficacy outcome

    In Japanese adults with uncontrolled type 2 diabetes, liraglutide 0.9 mg lowered HbA1c significantly more than each DPP-4 inhibitor at 24 weeks.

    In plain wordsIn Japanese adults with type 2 diabetes, liraglutide 0.9 mg lowered HbA1c more than each DPP-4 inhibitor at 24 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at 24 weeks, liraglutide 0.9 mg vs DPP-4 inhibitors
    Study

    n = 2,091

    Comparator
    DPP-4 inhibitors
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide 0.9 mg was statistically superior to all DPP-4 interventions (vildagliptin, sitagliptin, linagliptin, alogliptin, teneligliptin, trelagliptin and omarigliptin) at 12 weeks and 24 weeks among those reporting.
    2 context sentences
    Summary · context
    A total of 27 trials (5032 patients) reported change in HbA1c at 12 weeks and at 24 weeks 9 trials (2091 patients).
    Summary · context
    We searched for randomized controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016.
  3. 03HumanSystematic reviewEfficacy outcome

    In Japanese adults with uncontrolled type 2 diabetes, weight change did not differ statistically between treatments, liraglutide and DPP-4 inhibitors.

    In plain wordsIn Japanese adults with type 2 diabetes, weight change did not clearly differ between liraglutide and DPP-4 inhibitors.

    Peptide
    Liraglutide
    Outcome
    No significant changeWeight change, liraglutide vs DPP-4 inhibitors
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatments were not statistically differentiable with respect to weight change and risk of hypoglycemia.
    1 context sentence
    Summary · context
    We searched for randomized controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016.
  4. 04HumanSystematic reviewSafety outcome

    In Japanese adults with uncontrolled type 2 diabetes, the risk of hypoglycaemia did not differ statistically between treatments, liraglutide and DPP-4 inhibitors.

    In plain wordsIn Japanese adults with type 2 diabetes, the risk of low blood sugar did not clearly differ between liraglutide and DPP-4 inhibitors.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia risk, liraglutide vs DPP-4 inhibitors
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatments were not statistically differentiable with respect to weight change and risk of hypoglycemia.
    2 context sentences
    Summary · context
    Some important outcomes were limited by poor reporting (eGFR and microalbuminuria) or low event rates (hypoglycemia).
    Summary · context
    We searched for randomized controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In Japanese adults with uncontrolled type 2 diabetes, all treatments in the network, liraglutide and DPP-4 inhibitors, reduced HbA1c versus placebo at 12 and 24 weeks.

    In plain wordsIn Japanese adults with type 2 diabetes, all the diabetes drugs compared, including liraglutide, lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change versus placebo, all treatments
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    All treatments showed statistically significant reductions in HbA1c relative to placebo at 12 and 24 weeks.
    1 context sentence
    Summary · context
    We searched for randomized controlled trials (RCTs) evaluating outcomes among Japanese adults with uncontrolled T2DM and including liraglutide or DPP-4 inhibitors up to August 2016.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.